arrow
A

Andreas Kribben

university of duisburg essen
H指数:54
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hemoadsorption therapy in severe rhabdomyolysis: a report from the international, prospective COSMOS (CytOSorb® TreatMent of Critically ill PatientS) registry
2025-12-310
PRE
The Advanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS)

高级器官支持(ADVOS)血液透析系统实现了其预期目的:对来自体外多器官支持(EMOS)登记处282例患者的数据分析

2025-12-040
PRE
The international, prospective CytOSorbR○ treatMent Of critically ill patientS (COSMOS) registry: Interim results from the first 150 patients

Ferrer, R.; Thielmann, M.; Kribben, A.; Unglaube, M.; Tyczynski, B.; Kreutz, J.; Baumann, A.; Guenther, U.; Henzler, D.; Kirschning, T.; 等. 国际前瞻性CytOSorb®治疗危重患者(COSMOS)登记研究:前150例患者的中期结果。J. Intensiv. Med. 2025. [Google Scholar] [CrossRef]

2025-10-012
OAAI
Extracorporeal myoglobin elimination using the adsorber CytoSorb or the high-flux HF80 dialyzer for patients with severe rhabdomyolysis: a comparative study

使用吸附剂CytoSorb或高通量HF80透析器进行体外肌红蛋白清除,用于严重横纹肌溶解症患者的比较研究

2025-05-010
OA
Integrating the Patient Perspective into Healthcare and Real-World Evidence: The Multi-site, Cross-Disease, Patient-Centered Outcomes Research Project in the Medical Informatics Initiative (PCOR-MII)

将患者观点整合到医疗保健和现实世界的证据中: 医学信息学计划 (PCOR-MII) 中的多站点,跨疾病,以患者为中心的结果研究项目

2025-01-270
OAAI
Inhibiting the NADase CD38 improves cytomegalovirus-specific CD8+Tcell + Tcell functionality and metabolism
2024-07-020
OAAI
Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
2023-03-0124
OAAI